Lyrigabalin Capsule 75 mg (Pregabalin)
Pregabalin 75mg
Hard capsule · Prescription medication
Korea Shintex Pharmaceutical Co., Ltd.
MFDS item code 201906911 · Approved 2019.09.30
This product's status changed to Expired on 2024.09.30. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of neuropathic pain and fibromyalgia, and adjunctive treatment of epilepsy (partial-onset seizures)
This medication is used for the treatment of peripheral and central neuropathic pain in adults. It is also utilized as an adjunct therapy for partial seizures in patients with epilepsy, effective even in cases with or without secondary generalized symptoms. Additionally, it helps alleviate symptoms of fibromyalgia. Overall, it is very useful for treating neuropathic pain, neurological-related seizures, and myalgia.
This medicine is administered orally, with or without food, in 2 divided doses of the total daily dose of pregabalin. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with Renal Impairment’) 1. Neuropathic Pain 1) Peripheral Neuropathic Pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may thereafter be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central Neuropathic Pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, a dose reduction may be considered. (See section ‘4. Discontinuation of Treatment’) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may thereafter be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies were also conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys as unchanged drug. Since the clearance of this medicine is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. *: For women, multiply the result obtained from the above calculation by 0.85. This medicine is effectively removed from plasma by hemodialysis. (Approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Total daily dose of pregabalin: initial dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30 -<60: Total daily dose of pregabalin: initial dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15 -<30: Total daily dose of pregabalin: initial dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Total daily dose of pregabalin: initial dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: initial dose 25, maximum dose 100, single dose b TID = Total daily dose administered in 3 divided doses BID = Total daily dose administered in 2 divided doses QD = Administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the method of administration. b: The supplemental dose refers to an additional dose administered as a single dose. 6. Patients with Hepatic Impairment Dose adjustment is not necessary in patients with hepatic impairment. 8. Elderly Patients (65 years of age or older) Dose reduction may be necessary in elderly patients with impaired renal function.
Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12 ~17 years: Administration is not recommended because there are insufficient safety and efficacy data.
This medication may increase the risk of suicidal thoughts or behaviors, so if mood changes or symptoms of depression occur while taking this medication, consult a healthcare provider immediately. Patients with allergies to any ingredients in this medication or have genetic lactose metabolism disorders should not take it. Diabetic patients may find it challenging to control blood sugar due to weight gain, requiring dosage adjustments of blood sugar medications. If swelling occurs around the face or mouth due to hypersensitivity, cease taking the medication immediately. Elderly individuals should be cautious as they are at higher risk of falling or injury due to dizziness or drowsiness. If blurred vision or changes in vision occur, discontinue the medication and consult a healthcare provider. Suddenly discontinuing this medication can lead to withdrawal symptoms such as insomnia, headaches, nausea, anxiety, etc., so it should be tapered off gradually under medical supervision. Patients with a history of substance abuse may have a higher risk of misuse of this medication, so caution is advised during administration. Renal function-impaired patients may require dosage adjustments. Patients with severe heart disease should exercise caution while taking this medication. Concurrent use with central nervous system depressants, such as opioid analgesics, poses a risk of respiratory depression, and caution is warranted. Pregnant women are advised not to take this medication during early pregnancy due to the risk of fetal malformations, and women of childbearing age should use effective contraceptive methods. Breastfeeding women should consider discontinuing breastfeeding or the medication, as it may be excreted in breast milk. It is safest to avoid hazardous activities like driving or operating machinery until dizziness or drowsiness has resolved after taking the medication. In cases of severe skin rash or allergic reactions, cease taking the medication immediately and inform a healthcare provider. In case of overdose, confusion, drowsiness, depression, seizures may occur, requiring immediate emergency treatment. This medication should be kept out of reach of children and should not be transferred to other containers.
Not everyone experiences these, and they can vary from person to person.
This medication must be stored in a tightly sealed container to protect it from exposure to air or moisture. It is best stored at room temperature, between 15 to 30 degrees Celsius.
A hard capsule with a reddish-brown upper part and a white lower part containing white or pale yellow powder
30 capsules/bottle, 100 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Pregabalin 75mg
Hard capsule · Prescription medication
Korea Shintex Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.